MONTREAL, Dec. 7, 2025 /PRNewswire/ - Replicor Inc. announced the publication of data from its first global compassionate access program in the Journal of Hepatology (see here). About Replicor This compassionate access program, initiated with Dr. Marc Bourlière in France, deployed REP 2139-Mg in patients with chronic HBV / HDV infection who had failed on bulevirtide or lonafarnib and who had cirrhosis or decompensated cirrhosis. The access program treated 33 patients at 16 different sites in 8 different cou ...